Triwise Capital, an investment firm, led a $131m in Series B round in Immune-Onc Therapeutics, a clinical-stage cancer immunotherapy company, with participation from Proxima Ventures and Wuxi Biologics. "Immune-Onc had an incredible year of growth and development with two myeloid-checkpoint inhibitor programs progressing in the clinic in the US and China for multiple types of cancer where great unmet needs remain. We are confident in the long-term growth prospects for Immune-Onc and believe that our progress this past year provides a compelling foundation for continued success in 2023," Charlene Liao, Immune-Onc Founder and CEO.